Supplementary Table 4. Clinical characteristics and outcomes according to the SGLT2i prescription continuation at discharge

	SGLT2i withdrawal at discharge (n=14)	SGLT2i maintained at discharge (n=74)	P
Age (yr)	66.2±12.8	66.6±11.6	0.918
Male sex	8 (57.1)	49 (66.2)	0.729
Hypertension	13 (92.9)	63 (85.1)	0.728
Hyperlipidemia	13 (92.9)	59 (79.7)	0.430
Ever smoking	3 (21.4)	33 (44.6)	0.187
Stroke history	0 (0.0)	25 (33.8)	0.025
Atrial fibrillation	3 (21.4)	14 (18.9)	>0.999
Coronary heart disease	2 (14.3)	21 (28.4)	0.442
Heart failure	2 (14.3)	11 (14.9)	>0.999
HbA1c (%)	8.0 [7.0; 8.8]	7.8 [7.1; 9.1]	0.995
eGFR (mL/min/1.73 m^2)	75.1±25.9	74.6±19.1	0.936
Intracranial atherosclerosis	8 (57.1)	38 (51.4)	0.916
Total SVD score	1 [1; 3]	2 [1; 3]	0.197
Prestroke statin use	8 (57.1)	50 (67.6)	0.655
Prestroke mRS	0 [0; 0]	0 [0; 1]	0.281
Initial NIHSS	5.5 [2; 14]	3 [1; 5]	0.182
Intravenous thrombolysis	2 (14.3)	3 (4.1)	0.375
Endovascular thrombectomy	5 (35.7)	3 (4.1)	0.001
Stroke etiology			0.940
LAA	7 (50.0)	34 (45.9)	
SVO	2 (14.3)	16 (21.6)	
CE	3 (21.4)	15 (20.3)	
Others	2 (14.3)	9 (12.2)	
END	3 (21.4)	6 (8.1)	0.304
NIHSS at discharge	5 [2; 11]	2 [0; 3]	0.014
mRS at discharge	3.5 [1; 5]	1 [1; 3]	0.042
Favorable outcome at discharge	6 (42.9)	53 (71.6)	0.074
Excellent outcome at discharge	5 (35.7)	39 (52.7)	0.382
mRS at 3 months	4 [0; 5]	1 [0; 2]	0.006
Favorable outcome at 3 months	5 (35.7)	57 (77.0)	0.005
Excellent outcome at 3 months	4 (28.6)	49 (66.2)	0.019

The data are presented as n (%), mean±standard deviation, or median [interquartile range].
SGLT2i, sodium-glucose cotransporter 2 inhibitor; HbA1c, hemoglobin A1c; eGFR, estimated glomerular filtration rate; SVD, small vessel disease; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism; END, early neurological deterioration.

Supplementary Table 5. Balance after propensity score matching for the sensitivity analysis

	Mean control (n=288)	Mean SGLT2i (n=83)	SMD	RV
Propensity score	0.1907	0.1916	0.0070	1.0197
Age (yr)	67.3916	67.1928	−0.0170	1.0714
Male sex	0.6667	0.6506	−0.0336	-
Hypertension	0.8705	0.8554	−0.0439	-
Hyperlipidemia	0.7871	0.8072	0.0521	-
Ever smoking	0.3976	0.4096	0.0245	-
Stroke history	0.2821	0.3012	0.0423	-
Atrial fibrillation	0.1928	0.1807	−0.0305	-
Coronary heart disease	0.2610	0.2530	−0.0183	-
Heart failure	0.1265	0.1205	−0.0170	-
Active cancer	0.0000	0.0000	0.0000	-
HbA1c category (%)				
<7.0	0.2440	0.2410	−0.0072	-
≥7.0	0.7560	0.7590	0.0072	-
eGFR category (mL/min/1.73 m^2)				
≥60	0.7420	0.7590	0.0400	-
30–59	0.1888	0.1928	0.0104	-
15–29	0.0693	0.0482	−0.0911	-
<15	0.0000	0.0000	0.0000	-
Intracranial atherosclerosis	0.4940	0.5181	0.0482	-
Total SVD score	2.1084	2.0723	−0.0274	1.0818
Prestroke statin use	0.6466	0.6506	0.0085	-
Prestroke mRS	0.3745	0.3614	−0.0172	0.8701
Initial NIHSS	5.0070	4.6265	−0.0703	0.9462
Intravenous thrombolysis	0.0763	0.0602	−0.0694	-
Endovascular thrombectomy	0.0924	0.0964	0.0140	-
Stroke etiology				
LAA	0.4428	0.4819	0.0785	-
SVO	0.2239	0.2048	−0.0473	-
CE	0.1918	0.1807	−0.0274	-
Others	0.1416	0.1325	−0.0273	-

SGLT2i, sodium-glucose cotransporter 2 inhibitor; SMD, standardized mean difference; RV, ratio of variance; HbA1c, hemoglobin A1c; eGFR, estimated glomerular filtration rate; SVD, small vessel disease; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism.